<!doctype html><html lang=en><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><title>After red-hot IPO, Chinese biotech firm Kintor eyes blockbuster drugs for prostate cancer, sex hormo | VivaBlog</title><meta name=generator content="Hugo 0.98.0"><meta name=description content="“We believe both candidates have the potential to be blockbuster drugs in China and the US,” chief financial officer Lucy Lu Yan said in an interview.
03:06
Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful
Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful
Lu is hoping the results will give the Suzhou, Jiangsu province-based firm a shot at China’s rising demand for health care to underpin its earnings outlook."><link rel=stylesheet href=https://assets.cdnweb.info/hugo/cayman/css/normalize.css><link href="https://fonts.googleapis.com/css?family=Open+Sans:400,700" rel=stylesheet type=text/css><link rel=stylesheet href=https://assets.cdnweb.info/hugo/cayman/css/cayman.css><link rel=apple-touch-icon sizes=180x180 href=./apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=./favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=./favicon-16x16.png><link rel=stylesheet href=https://cdn.jsdelivr.net/npm/katex@0.10.2/dist/katex.min.css integrity=sha384-yFRtMMDnQtDRO8rLpMIKrtPCD5jdktao2TV19YiZYWMDkUR5GQZR/NOVTdquEx1j crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.10.2/dist/katex.min.js integrity=sha384-9Nhn55MVVN0/4OFx7EE5kpFBPsEMZxKTCnA+4fqDmg12eCTqGi6+BB2LjY8brQxJ crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.10.2/dist/contrib/auto-render.min.js integrity=sha384-kWPLUVMOks5AQFrykwIup5lo0m3iMkkHrD0uJ4H5cjeGihAutqP0yW0J6dpFiVkI crossorigin=anonymous onload=renderMathInElement(document.body)></script></head><body><section class=page-header><h1 class=project-name>VivaBlog</h1><h2 class=project-tagline></h2><nav><a href=./index.html class=btn>Blog</a>
<a href=./sitemap.xml class=btn>Sitemap</a>
<a href=./index.xml class=btn>RSS</a></nav></section><section class=main-content><h1>After red-hot IPO, Chinese biotech firm Kintor eyes blockbuster drugs for prostate cancer, sex hormo</h1><div><strong>Publish date: </strong>2024-07-17</div><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“We believe both candidates have the potential to be blockbuster drugs in China and the US,” chief financial officer Lucy Lu Yan said in an interview.</p><img data-qa=BaseImage-handleRenderImage-StyledImage src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2020/05/01/cleanthumbnail.jpg style=margin:auto;display:block;text-align:center><p data-qa=SCMPYoutubeVideoPreview-PreviewDuration class="css-dkee4u eaw92su1">03:06</p><p data-qa=SCMPYoutubeVideoPreview-PreviewTitle class="css-1ajvbe4 eaw92su2">Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful</p><p>Chinese firm ready to make 100 million Coronavirus vaccine doses if trials are successful</p>Lu is hoping the results will give the Suzhou, Jiangsu province-based firm a shot at China’s rising <a class="euc41pk0 e13op9j60 e1qbu6wp1 css-jgjyn2 ef1hf1w0" href=# data-qa=BaseLink-renderAnchor-StyledAnchor><span data-qa=Component-Text class="css-0 e1qbu6wp0">demand for health care</span></a> to underpin its earnings outlook. The size of the domestic market for both treatments is worth 24.4 billion yuan (US$3.4 billion) by 2025, according to Frost & Sullivan.Kintor surged 6.7 per cent to close at HK$21.50 on its Hong Kong debut in a market hobbled by political tensions caused by a controversial plan to introduce a national security law in the city. The <a class="euc41pk0 e13op9j60 e1qbu6wp1 css-jgjyn2 ef1hf1w0" href=# data-qa=BaseLink-renderAnchor-StyledAnchor><span data-qa=Component-Text class="css-0 e1qbu6wp0">Hang Seng Index tumbled</span></a> 5.6 per cent, the most since July 2015.<p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Proxalutamide slows or stops cancer growth by inhibiting androgens, male hormones that stimulate prostate cancer cells, from binding to their receptors. Topical drug pyrilutamide blocks androgens’ signalling to prevent hair loss.</p><img style=margin:auto;display:block;text-align:center;max-width:100%;height:auto src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2020/05/01/cleanthumbnail.jpg><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Early results from those trials on 105 prostate cancer patients in China who previously had chemotherapy are encouraging, according to chief executive officer Tong Youzhi.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Their average tumour growth-free survival time in the phase two trials was 11.2 months, Tong said. This compared to 8.3 months among patients (who had no chemotherapy treatment) in phase three trials of enzalutamide in China, a therapy developed on Astellas Pharma.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“From these data, we feel comfortable to say we have better efficacy among Chinese patients,” said Tong, who previously worked at US drugs developer Angion Biomedica before founding Kintor Pharmaceutical in 2009.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Enzalutamide is the only approved oral drug in the US for three forms of late-stage prostate cancer. It was approved last November in China and went on sale in March.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">China’s prostate drug market may grow to 21.3 billion yuan in 2025 from 4.7 billion yuan last year, according to Frost & Sullivan. Enzalutamide had 36 per cent of the US market worth US$5.9 billion in 2018.</p><h3 type=h3 data-qa=Component-Component class="e14khtrb0 css-17x7qa9 e793b7w1"><a class="link-text css-e0dnmk ef1hf1w0" href=# data-qa=BaseLink-renderAnchor-StyledAnchor><p><span data-qa=DigitalArchiveLink-TitleText class="css-66qo9a eeeqn932">Chinese cancer drug firm Akesobio’s US$330 million IPO – Hong Kong’s largest this year – is oversubscribed 639 times by city’s investors</span></p></a></h3><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">For hair loss drug candidate pyrilutamide, Kintor aims to take on Johnson & Johnson’s minoxidil, which has about 70-75 per cent of the market in China and the US. Merck’s finasteride has the rest of the sales.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Phase one trials showed pyrilutamide is safe, Kintor said. Efficacy data will be produced by phase two trials. The market for hair-loss drugs will be worth 3.1 billion yuan in China by 2025, versus 1.47 billion yuan in 2018, according to Frost & Sullivan.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Kintor’s offering of 9.2 million shares to Hong Kong retail investors was 551 times subscribed, while 92.3 million shares allotted to international investors were over eight times subscribed.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">The previous four biotech stocks listed in Hong Kong since December recorded retail subscription rates of 192 to 639 times. They have risen by 66 to 109 per cent since their listings.</p><img data-qa=BaseImage-handleRenderImage-StyledImage src=https://cdn.statically.io/img/cdn.i-scmp.com/sites/default/files/styles/wide_landscape/public/d8/video/thumbnail/2019/11/11/clean_1.jpg style=margin:auto;display:block;text-align:center><p data-qa=SCMPYoutubeVideoPreview-PreviewDuration class="css-dkee4u eaw92su1">04:23</p><p data-qa=SCMPYoutubeVideoPreview-PreviewTitle class="css-1ajvbe4 eaw92su2">Government support can help Hong Kong become China’s biotech ‘nerve centre’</p><p>Government support can help Hong Kong become China’s biotech ‘nerve centre’</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Since it is difficult for retail investors to differentiate which biotech companies are likely to achieve commercial success, many are short term speculation-minded, noted Francis Lun Sheung-nim, chief executive officer of GEO Securities. “This sort of easy profit will not last long.”</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">Given recent rallies in Chinese health care stocks, especially biotech companies, some analysts and investors are concerned about the valuations of pre-revenue companies, noted Jay Lee, an analyst at Morningstar Investment Management.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">“Although we do not view the whole sector as significantly overvalued yet, we have changed the ratings for a number of stocks from buy to hold in recent weeks,” he said.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">For innovative drug developers, listing candidates that have a diverse portfolio of drug candidates and a clear research focus are preferred, since even drug candidates with promising early-stage trials data can fail in later stage trials, Lee added.</p><p datatype="p" data-qa=Component-Component class="e15kmbpe0 css-1c6uqr6 e1346ty31">&nbsp;</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmivp6x7tK%2FMqWWcp51kr7a%2FyKecrKtfmLyuvMCnoJ6rX5a%2FtbXCpZxoa2BtgnaClWiYn6yVp3qzscNmn6isXZ69sHnCoaCnnaOaeqO1zq2cnKBdm7azuYykoKesn6d6psXErGSbpJ%2BYuKPB0q2cqw%3D%3D</p><footer class=site-footer><span class=site-footer-credits>Made with <a href=https://gohugo.io/>Hugo</a>. © 2022. All rights reserved.</span></footer></section><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/floating.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://js.zainuddin.my.id/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>